Halozyme Therapeutics
HALO
Dorian LPG
LPG
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
Teradata Corp
TDC
Hutchmed (China)
HCM
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 3.33%4.06B | 5.96%3.56B | 8.41%2.89B | 10.05%12.84B | 10.28%2.89B | 8.57%3.93B | 5.56%3.36B | 18.50%2.67B | 35.69%11.67B | 14.87%2.62B |
Operating revenue | 3.33%4.06B | 5.96%3.56B | 8.41%2.89B | 10.05%12.84B | 10.28%2.89B | 8.57%3.93B | 5.56%3.36B | 18.50%2.67B | 35.69%11.67B | 14.87%2.62B |
Cost of revenue | -5.83%388M | -11.06%362M | -13.53%358M | -5.07%1.57B | -17.48%340M | -9.45%412M | -2.86%407M | 11.59%414M | 8.87%1.66B | 4.30%412M |
Gross profit | 4.41%3.67B | 8.30%3.2B | 12.44%2.53B | 12.55%11.27B | 15.46%2.55B | 11.16%3.52B | 6.84%2.95B | 19.86%2.25B | 41.46%10.01B | 17.09%2.21B |
Operating expense | 8.24%2.81B | 7.94%2.71B | 8.70%2.57B | 11.09%9.8B | 11.98%2.33B | 9.85%2.6B | 5.07%2.51B | 18.83%2.37B | 29.45%8.82B | 22.24%2.08B |
Selling and administrative expenses | 11.27%2.28B | 10.49%2.17B | 8.83%2.02B | 11.48%7.63B | 12.80%1.76B | 10.45%2.05B | 3.10%1.96B | 21.84%1.86B | 39.02%6.85B | 27.30%1.56B |
-Selling and marketing expense | 10.56%2.05B | 12.43%1.99B | 9.68%1.84B | 12.51%6.86B | 13.59%1.56B | 11.20%1.86B | 3.15%1.77B | 25.02%1.67B | 44.52%6.1B | 31.80%1.38B |
-General and administrative expense | 18.04%229M | -7.22%180M | 1.09%186M | 3.07%771M | 6.99%199M | 3.74%194M | 2.65%194M | -1.08%184M | 6.10%748M | 1.64%186M |
Research and development costs | -5.88%320M | -3.78%331M | 7.57%341M | 14.99%1.36B | 12.62%357M | 9.68%340M | 21.13%344M | 17.41%317M | 9.96%1.18B | 15.69%317M |
Depreciation amortization depletion | 1.44%211M | 3.02%205M | 9.38%210M | 1.89%807M | 4.52%208M | 4.52%208M | 1.02%199M | -2.54%192M | -2.70%792M | 0.00%199M |
-Depreciation and amortization | 1.44%211M | 3.02%205M | 9.38%210M | 1.89%807M | 4.52%208M | 4.52%208M | 1.02%199M | -2.54%192M | -2.70%792M | 0.00%199M |
Operating profit | -6.42%860M | 10.36%490M | 63.79%-42M | 23.38%1.47B | 71.88%220M | 15.02%919M | 18.09%444M | -1.75%-116M | 353.82%1.19B | -30.43%128M |
Net non-operating interest income expense | 200.00%6M | 200.00%6M | 38.89%-11M | 82.49%-38M | 51.52%-16M | 86.05%-6M | 103.17%2M | 76.92%-18M | 36.55%-217M | 58.75%-33M |
Non-operating interest income | 19.64%67M | 6.35%67M | 18.60%51M | 245.00%207M | 66.67%45M | 180.00%56M | 530.00%63M | 1,333.33%43M | 566.67%60M | 575.00%27M |
Non-operating interest expense | -1.61%61M | 0.00%61M | 1.64%62M | -11.55%245M | 1.67%61M | -1.59%62M | -16.44%61M | -24.69%61M | -21.08%277M | -28.57%60M |
Other net income (expense) | 101.71%8M | -144.44%-8M | -239.73%-102M | 5.30%-411M | -137.50%-33M | -610.61%-469M | 104.09%18M | 556.25%73M | -1,133.33%-434M | -76.02%88M |
Gain on sale of security | 167.09%106M | 38.89%25M | -225.00%-39M | 82.08%-69M | -2.35%83M | -81.61%-158M | 104.65%18M | -400.00%-12M | -400.00%-385M | 403.57%85M |
Special income (charges) | 69.23%-96M | -1,400.00%-39M | -533.33%-65M | -734.69%-409M | -2,975.00%-115M | -1,585.71%-312M | 105.45%3M | 178.95%15M | -149.00%-49M | -98.95%4M |
-Less:Restructuring and merger&acquisition | --6M | --18M | --48M | --0 | --0 | --0 | --0 | --0 | --0 | ---- |
-Less:Impairment of capital assets | -89.42%33M | ---- | ---- | 425.93%426M | --114M | 500.00%312M | ---- | ---- | 305.00%81M | --0 |
-Less:Other special charges | --59M | 2,000.00%21M | 300.00%20M | 130.77%8M | --2M | ---- | -96.15%1M | -76.19%5M | -109.25%-26M | --0 |
-Gain on sale of business | --2M | --0 | -85.00%3M | 316.67%25M | -75.00%1M | --0 | --4M | 900.00%20M | -98.68%6M | -99.00%4M |
Other non- operating income (expenses) | -300.00%-2M | 300.00%6M | -97.14%2M | --67M | ---1M | --1M | -250.00%-3M | 7,100.00%70M | ---- | ---- |
Income before tax | 96.85%874M | 5.17%488M | -154.10%-155M | 89.22%1.02B | -6.56%171M | -35.65%444M | 465.35%464M | 70.67%-61M | 1,515.79%538M | -61.15%183M |
Income tax | 36.69%190M | 46.75%113M | -124.05%-19M | 69.23%330M | 337.50%35M | -35.05%139M | 32.76%77M | 192.94%79M | 467.92%195M | -89.47%8M |
Net income | 124.26%684M | -3.10%375M | 2.86%-136M | 100.58%688M | -22.29%136M | -35.92%305M | 309.19%387M | -13.82%-140M | 2,186.67%343M | -55.70%175M |
Net income continuous Operations | 124.26%684M | -3.10%375M | 2.86%-136M | 100.58%688M | -22.29%136M | -35.92%305M | 309.19%387M | -13.82%-140M | 2,186.67%343M | -55.70%175M |
Minority interest income | 0 | -650.00%-11M | -120.00%-1M | -1,111.11%-109M | 300.00%4M | -1,900.00%-120M | 2M | 600.00%5M | -400.00%-9M | -122.22%-2M |
Net income attributable to the parent company | 60.94%684M | 0.26%386M | 6.90%-135M | 126.42%797M | -25.42%132M | -11.83%425M | 308.11%385M | -18.85%-145M | 2,833.33%352M | -54.15%177M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | 0 | 0 | ||||||||
Net income attributable to common stockholders | 60.94%684M | 0.26%386M | 6.90%-135M | 126.42%797M | -25.42%132M | -11.83%425M | 308.11%385M | -18.85%-145M | 230.86%352M | -35.87%177M |
Basic earnings per share | 77.18%5.28 | 11.45%2.92 | -4.21%-0.99 | 145.54%5.5 | -15.79%0.96 | -2.30%2.98 | 323.93%2.62 | -21.79%-0.95 | 224.44%2.24 | -36.67%1.14 |
Diluted earnings per share | 75.61%5.04 | 10.24%2.8 | -4.21%-0.99 | 144.70%5.31 | -17.12%0.92 | -3.69%2.87 | 317.09%2.54 | -21.79%-0.95 | 220.56%2.17 | -34.71%1.11 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |